ATCC Licensing Program Aids Genmab Drug Development.MANASSAS, Va. -- ATCC ATCC American Type Culture Collection, see there (R) announced today the signing of a license agreement with Genmab A/S that supplies the biotechnology firm with an ATCC cell line standard for drug in vitro in vitro /in vi·tro/ (in ve´tro) [L.] within a glass; observable in a test tube; in an artificial environment. in vi·tro adj. In an artificial environment outside a living organism. consistency studies. The worldwide, non-exclusive Genmab agreement is the latest in a series of commercial licensing arrangements that enable highly characterized ATCC biological materials to be used for a variety of industrial R&D purposes. Genmab A/S develops human antibodies for the treatment of a wide range of diseases, including cancer, infectious disease Infectious disease A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. and autoimmune disorders Autoimmune Disorders Definition Autoimmune disorders are conditions in which a person's immune system attacks the body's own cells, causing tissue destruction. . The ATCC-Genmab agreement will allow the biotech firm to employ an ATCC cell line standard in testing the potency of manufacturing batches of human monoclonal antibodies This is a list of monoclonal antibodies, antibodies which are clones of a single parent cell. When used as medications, the generic names end in -mab (see "Nomenclature of monoclonal antibodies"). that the company is developing. The assays will be used with Genmab antibodies designed to recognize specific cell surface receptors. "ATCC is delighted to have the chance to provide our biomaterials to Genmab as they navigate the final stages of drug development," said ATCC VP for Licensing, Contracts and Compliance Jesus Soriano, MD/PhD. "Arrangements such as the one between ATCC and Genmab reflect ATCC's willingness to address the increasing demand for commercial use of ATCC biological standards." ATCC's non-exclusive licensing program ensures equitable access to reference research materials that are otherwise available under the ATCC Material Transfer Agreement, a contract that limits the use of ATCC biomaterials to non-commercial scientific research. About ATCC Founded in 1925, ATCC is the world's premier global independent biological resource center. Its mission is to acquire, authenticate, preserve, produce, develop and share biological materials for the advancement of scientific knowledge. ATCC provides these core services The introduction to this article provides insufficient context for those unfamiliar with the subject matter. Please help [ improve the introduction] to meet Wikipedia's layout standards. You can discuss the issue on the talk page. in government, industry, education, health care and research laboratories around the world. For more information, visit: www.atcc.org. About Genmab A/S Genmab A/S is a biotechnology company that creates and develops human antibodies for disease treatment. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis rheumatoid arthritis Chronic, progressive autoimmune disease causing connective-tissue inflammation, mostly in synovial joints. It can occur at any age, is more common in women, and has an unpredictable course. and other inflammatory conditions. At present, Genmab has multiple partnerships to gain access to disease targets and develop novel human antibodies. Genmab has operations in Denmark, the Netherlands and the U.S. For more information, visit: www.genmab.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion